Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Winther Kirsten) > Overexpression of t...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		05288naa a2200409 4500
001		oai:lup.lub.lu.se:30b38a16-85a1-443a-bc1b-d97923c4417a
003		SwePub
008		230224s2023 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://lup.lub.lu.se/record/30b38a16-85a1-443a-bc1b-d97923c4417a2 URI
024	7	a https://doi.org/10.3324/haematol.2022.2814202 DOI
040		a (SwePub)lu
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Sandström Gerdtsson, Annau Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)an1350sa
245	1 0	a Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
264		c 2022-12-15
264	1	b Ferrata Storti Foundation (Haematologica),c 2023
520		a The variable outcome to standard immunochemotherapy for mantle cell lymphoma (MCL) patients is a clinical challenge. Established risk factors, including high MCL international prognostic index (MIPI), high proliferation (Ki-67), non-classic (blastoid/pleomorphic) morphology, and mutated TP53, only partly identify patients in need of alternative treatment. Deepened understanding of biological factors that influence time to progression and relapse would allow for an improved stratification, and identification of novel targets for high-risk patients. We performed gene expression analyses to identify pathways and genes associated with outcome in a cohort of homogeneously treated patients. In addition to deregulated proliferation, we show that thermogenesis, fatty acid degradation and oxidative phosphorylation are altered in patients with poor survival, and that high expression of carnitine palmitoyltransferase 1A (CPT1A), an enzyme involved in fatty acid degradation, can specifically identify high-risk patients independent of the established high-risk factors. We suggest that complementary investigations of metabolism may increase the accuracy of patient stratification and that immunohistochemistry-based assessment of CPT1A can contribute to defining high-risk MCL.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
700	1	a de Matos Rodrigues, Joanau Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)jo8141ro
700	1	a Eskelund, Christian Wintheru Copenhagen University Hospital4 aut
700	1	a Husby, Simonu Copenhagen University Hospital4 aut
700	1	a Gronbaek, Kirstenu Copenhagen University Hospital4 aut
700	1	a Räty, Riikkau Helsinki University Central Hospital4 aut
700	1	a Kolstad, Arneu Oslo university hospital4 aut
700	1	a Geisler, Christian H.u Copenhagen University Hospital4 aut
700	1	a Porwit, Annau Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)an6742po
700	1	a Jerkeman, Matsu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Onkologi övergripande,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lymphoma - Clinical Research,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Oncology corporate,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-mje
700	1	a Ek, Sarau Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments4 aut0 (Swepub:lu)immt-san
710	2	a Institutionen för immunteknologib Institutioner vid LTH4 org
773	0	t Haematologicad : Ferrata Storti Foundation (Haematologica)g 108:4, s. 1092-1104q 108:4<1092-1104x 0390-6078x 1592-8721
856	4	u http://dx.doi.org/10.3324/haematol.2022.281420x freey FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/30b38a16-85a1-443a-bc1b-d97923c4417a
856	4 8	u https://doi.org/10.3324/haematol.2022.281420

Hitta via bibliotek

Haematologica (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Sandström Gerdts ...; de Matos Rodrigu ...; Eskelund, Christ ...; Husby, Simon; Gronbaek, Kirste ...; Räty, Riikka; visa fler...; Kolstad, Arne; Geisler, Christi ...; Porwit, Anna; Jerkeman, Mats; Ek, Sara; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: Haematologica

Av lärosätet: Lunds universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se